Beam Therapeutics Inc (BEAM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.36B
Last updated: Nov 17, 2026 at 11:05 AM ET
Beam Therapeutics Inc (BEAM) Stock Forecast
Analysts expect Beam Therapeutics (BEAM) to earn -$4.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $38.51M. Of 15 analysts, 13 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 87% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.7% |
| Buy | 12 | 80.0% |
| Hold | 2 | 13.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 18.9%.
- Fiscal year ending Dec 31, 2026
- -$4.53
- EPS consensus, revenue $38.51M
- Fiscal year ending Dec 31, 2027
- -$5.01
- EPS consensus, revenue $31.22M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.53 | -$4.73 to -$3.76 | 14 | $38.51M | $32.84M to $48.50M | 13 |
| Dec 31, 2027 | -$5.01 | -$6.15 to -$3.56 | 15 | $31.22M | $1.23M to $50.00M | 13 |
Quarterly Estimates
The EPS consensus rises from -$1.25 for the quarter ending Dec 31, 2026 to -$1.24 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.25 | -$1.32 to -$1.19 | 17 | $6.30M | N/A | 16 |
| Mar 31, 2027 | -$1.24 | -$1.25 to -$1.23 | 2 | $400000 | $300000 to $500000 | 2 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 5 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.45.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.53 | -$4.42 | -$4.45 | -$4.45 | -$4.45 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.01 | -$4.76 | -$4.74 | -$4.74 | -$4.74 | N/A |
| Quarter ending Mar 31, 2027 | -$1.24 | -$1.21 | -$1.20 | -$1.20 | -$1.20 | N/A |
Frequently Asked Questions About BEAM
What is the BEAM stock forecast?
Consensus analyst estimates put Beam Therapeutics's EPS at -$4.53 for the fiscal year ending Dec 31, 2026, on revenue of $38.51M. The consensus rating from 15 analysts is Buy.
How do analysts rate BEAM stock?
Of 15 analysts covering Beam Therapeutics, 1 rates it Strong Buy, 12 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BEAM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.53, with estimates from -$4.73 to -$3.76 from 14 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.01, with estimates from -$6.15 to -$3.56 from 15 analysts.
What revenue do analysts expect from Beam Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $38.51M, with estimates from $32.84M to $48.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $31.22M, with estimates from $1.23M to $50.00M.
How many analysts cover BEAM?
15 analysts rate Beam Therapeutics stock, and 14 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BEAM pages: Overview, Earnings, Forecast, Financials, Competitors